TY - JOUR
T1 - Association of Mortality and Risk of Epilepsy with Type of Acute Symptomatic Seizure after Ischemic Stroke and an Updated Prognostic Model
AU - Sinka, Lucia
AU - Abraira, Laura
AU - Imbach, Lukas L.
AU - Zieglgänsberger, Dominik
AU - Santamarina, Estevo
AU - Álvarez-Sabín, José
AU - Ferreira-Atuesta, Carolina
AU - Katan, Mira
AU - Scherrer, Natalie
AU - Bicciato, Giulio
AU - Terziev, Robert
AU - Simmen, Cyril
AU - Schubert, Kai Michael
AU - Elshahabi, Adham
AU - Baumann, Christian R.
AU - Döhler, Nico
AU - Erdélyi-Canavese, Barbara
AU - Felbecker, Ansgar
AU - Siebel, Philip
AU - Winklehner, Michael
AU - Von Oertzen, Tim J.
AU - Wagner, Judith N.
AU - Gigli, Gian Luigi
AU - Serafini, Anna
AU - Nilo, Annacarmen
AU - Janes, Francesco
AU - Merlino, Giovanni
AU - Valente, Mariarosaria
AU - Zafra-Sierra, María Paula
AU - Bayona-Ortiz, Hernan
AU - Conrad, Julian
AU - Evers, Stefan
AU - Lochner, Piergiorgio
AU - Roell, Frauke
AU - Brigo, Francesco
AU - Bentes, Carla
AU - Peralta, Ana Rita
AU - Pinho E Melo, Teresa
AU - Keezer, Mark R.
AU - Duncan, John S.
AU - Sander, Josemir W.
AU - Tettenborn, Barbara
AU - Koepp, Matthias J.
AU - Galovic, Marian
N1 - Publisher Copyright:
© 2023 American Medical Association. All rights reserved.
PY - 2023/6/12
Y1 - 2023/6/12
N2 - Importance: Acute symptomatic seizures occurring within 7 days after ischemic stroke may be associated with an increased mortality and risk of epilepsy. It is unknown whether the type of acute symptomatic seizure influences this risk. Objective: To compare mortality and risk of epilepsy following different types of acute symptomatic seizures. Design, Setting, and Participants: This cohort study analyzed data acquired from 2002 to 2019 from 9 tertiary referral centers. The derivation cohort included adults from 7 cohorts and 2 case-control studies with neuroimaging-confirmed ischemic stroke and without a history of seizures. Replication in 3 separate cohorts included adults with acute symptomatic status epilepticus after neuroimaging-confirmed ischemic stroke. The final data analysis was performed in July 2022. Exposures: Type of acute symptomatic seizure. Main Outcomes and Measures: All-cause mortality and epilepsy (at least 1 unprovoked seizure presenting >7 days after stroke). Results: A total of 4552 adults were included in the derivation cohort (2547 male participants [56%]; 2005 female [44%]; median age, 73 years [IQR, 62-81]). Acute symptomatic seizures occurred in 226 individuals (5%), of whom 8 (0.2%) presented with status epilepticus. In patients with acute symptomatic status epilepticus, 10-year mortality was 79% compared with 30% in those with short acute symptomatic seizures and 11% in those without seizures. The 10-year risk of epilepsy in stroke survivors with acute symptomatic status epilepticus was 81%, compared with 40% in survivors with short acute symptomatic seizures and 13% in survivors without seizures. In a replication cohort of 39 individuals with acute symptomatic status epilepticus after ischemic stroke (24 female; median age, 78 years), the 10-year risk of mortality and epilepsy was 76% and 88%, respectively. We updated a previously described prognostic model (SeLECT 2.0) with the type of acute symptomatic seizures as a covariate. SeLECT 2.0 successfully captured cases at high risk of poststroke epilepsy. Conclusions and Relevance: In this study, individuals with stroke and acute symptomatic seizures presenting as status epilepticus had a higher mortality and risk of epilepsy compared with those with short acute symptomatic seizures or no seizures. The SeLECT 2.0 prognostic model adequately reflected the risk of epilepsy in high-risk cases and may inform decisions on the continuation of antiseizure medication treatment and the methods and frequency of follow-up.
AB - Importance: Acute symptomatic seizures occurring within 7 days after ischemic stroke may be associated with an increased mortality and risk of epilepsy. It is unknown whether the type of acute symptomatic seizure influences this risk. Objective: To compare mortality and risk of epilepsy following different types of acute symptomatic seizures. Design, Setting, and Participants: This cohort study analyzed data acquired from 2002 to 2019 from 9 tertiary referral centers. The derivation cohort included adults from 7 cohorts and 2 case-control studies with neuroimaging-confirmed ischemic stroke and without a history of seizures. Replication in 3 separate cohorts included adults with acute symptomatic status epilepticus after neuroimaging-confirmed ischemic stroke. The final data analysis was performed in July 2022. Exposures: Type of acute symptomatic seizure. Main Outcomes and Measures: All-cause mortality and epilepsy (at least 1 unprovoked seizure presenting >7 days after stroke). Results: A total of 4552 adults were included in the derivation cohort (2547 male participants [56%]; 2005 female [44%]; median age, 73 years [IQR, 62-81]). Acute symptomatic seizures occurred in 226 individuals (5%), of whom 8 (0.2%) presented with status epilepticus. In patients with acute symptomatic status epilepticus, 10-year mortality was 79% compared with 30% in those with short acute symptomatic seizures and 11% in those without seizures. The 10-year risk of epilepsy in stroke survivors with acute symptomatic status epilepticus was 81%, compared with 40% in survivors with short acute symptomatic seizures and 13% in survivors without seizures. In a replication cohort of 39 individuals with acute symptomatic status epilepticus after ischemic stroke (24 female; median age, 78 years), the 10-year risk of mortality and epilepsy was 76% and 88%, respectively. We updated a previously described prognostic model (SeLECT 2.0) with the type of acute symptomatic seizures as a covariate. SeLECT 2.0 successfully captured cases at high risk of poststroke epilepsy. Conclusions and Relevance: In this study, individuals with stroke and acute symptomatic seizures presenting as status epilepticus had a higher mortality and risk of epilepsy compared with those with short acute symptomatic seizures or no seizures. The SeLECT 2.0 prognostic model adequately reflected the risk of epilepsy in high-risk cases and may inform decisions on the continuation of antiseizure medication treatment and the methods and frequency of follow-up.
UR - http://www.scopus.com/inward/record.url?scp=85162037223&partnerID=8YFLogxK
U2 - 10.1001/jamaneurol.2023.0611
DO - 10.1001/jamaneurol.2023.0611
M3 - Article
C2 - 37036702
AN - SCOPUS:85162037223
SN - 2168-6149
VL - 80
SP - 605
EP - 613
JO - JAMA Neurology
JF - JAMA Neurology
IS - 6
ER -